Powers G.L. et al. discovered that bortezomib induced a dramatic decrease in ERα mRNA in breast cancer cells, due to direct transcriptional inhibition and loss of RNA polymerase II recruitment on the ERα gene promoter [99]. Here, ESR1 is linked to breast carcinoma.